Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Part 3 Specific Therapeutic Areas
- Chapter 17 Psychotropic Drug Treatment in Childhood and Adolescence
- Chapter 18 Psychotropic Drug Treatment in Later Life
- Chapter 19 Psychotropic Prescribing in Pregnancy and Lactation
- Chapter 20 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation
- Chapter 21 Antipsychotics, Weight Gain and Metabolic Risk
- Index
- References
Chapter 17 - Psychotropic Drug Treatment in Childhood and Adolescence
from Part 3 - Specific Therapeutic Areas
Published online by Cambridge University Press: 29 May 2020
Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Part 3 Specific Therapeutic Areas
- Chapter 17 Psychotropic Drug Treatment in Childhood and Adolescence
- Chapter 18 Psychotropic Drug Treatment in Later Life
- Chapter 19 Psychotropic Prescribing in Pregnancy and Lactation
- Chapter 20 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation
- Chapter 21 Antipsychotics, Weight Gain and Metabolic Risk
- Index
- References
Summary
Whilst the use of medication to treat psychiatric problems is less common in children and adolescents than in adults, rates of prescription are increasing for these groups. Notwithstanding a significant increase in the number and quality of clinical trials of psychotropic medications in children and adolescents there are continuing concerns that increases in rates of prescribing still outstrip the evidence base. For example, the prescribing of antipsychotics for children 7–12 years of age in primary care within the UK almost tripled between 1992 and 2005, with the prescribing of ‘atypical antipsychotics’ increasing 60-fold from 1994 to 2005 (Rani et al., 2008).
- Type
- Chapter
- Information
- Seminars in Clinical Psychopharmacology , pp. 525 - 542Publisher: Cambridge University PressPrint publication year: 2020
References
Allen, AJ, Kurlan, RM, Gilbert, DL, et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941–1949.Google Scholar
Baldwin, DS, Kosky, N (2007). Off-label prescribing in psychiatric practice. Adv Psychiatr Treat, 13, 414–422.CrossRefGoogle Scholar
Bratt, AM, Masanyero-Bennie, B, Kelley, SP (2017). A meta-analysis of the efficacy of immediate release methylphenidate to reduce hyperactivity in children with autistic spectrum disorder. J Pharm Sci Exp Pharmacol, 2017, 11–20.Google Scholar
Brent, D, Emslie, G, Clarke, G (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA, 299, 901–913.Google Scholar
Cipriani, A, Zhou, X, Del Giovane, C, et al. (2016). Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet, 388, 881–890.Google Scholar
Coghill, D, Seth, S (2015). Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. Child Adolesc Psychiatry Ment Health, 9, 52. doi:10.1186/s13034-015-0083-2.CrossRefGoogle ScholarPubMed
Cohen, SC, Mulqueen, JM, Ferracioli-Oda, E, et al. (2015). Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry, 54, 728–736.Google Scholar
Cortese, S, Holtmann, M, Banaschewski, T, et al. (2013). Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry, 54, 227–246.Google Scholar
Eddy, CM, Cavanna, AE, Gulisano, M, et al. (2011). Clinical correlates of quality of life in Tourette syndrome. Mov Disord, 26, 735–738.CrossRefGoogle ScholarPubMed
Emslie, GJ, Mayes, T, Porta, G, et al. (2010). Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes. Am J Psychiatry, 167, 782–791.CrossRefGoogle ScholarPubMed
European Medicines Agency (2007). Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use, as amended by Regulation (EC) No 1902/2006 (online). Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000068.jsp (last accessed 12.6.18).Google Scholar
Fraguas, D, Correll, CU, Merchan-Naranjo, J, et al. (2011). Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol, 21, 621–645.Google Scholar
Gibbons, RD, Brown, CH, Hur, K, et al. (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry, 164, 1356–1363.CrossRefGoogle ScholarPubMed
Goodyer, I, Dubicka, B, Wilkinson, P, et al. (2007). Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ, 335, 142.Google Scholar
Gusmao, R, Quintao, S, McDaid, D, et al. (2013). Antidepressant utilization and suicide in Europe: an ecological multi-national study. PLoS One, 8, e66455.Google Scholar
Hammad, TA, Laughren, T, Racoosin, J (2006). Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry, 63(3), 332–339.Google Scholar
Hazell, P, Mirzaie, M (2013). Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev, (6), CD002317.Google Scholar
Hetrick, SE, McKenzie, JE, Cox, GR, Simmons, MB, Merry, SN (2012). Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev, (11), CD004851.Google ScholarPubMed
Hollander, E, Phillips, A, Chaplin, W, et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582–589.Google Scholar
Hollander, E, Chaplin, W, Soorya, L, et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35, 990–998.Google Scholar
Joint Formulary Committee (2019). British National Formulary for Children (online). London: BMJ Group and Pharmaceutical Press.Google Scholar
Kendall, T, Hollis, C, Stafford, M, Taylor, C; Guideline Development Group (2013). Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ, 346, f150.Google Scholar
Le Noury, J, Nardo, JM, Healy, D, et al. (2015). Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351, h4320.CrossRefGoogle ScholarPubMed
Leslie, LK, Newman, TB, Chesney, PJ, et al. (2005). The Food and Drug Administration’s deliberations on antidepressant use in pediatric patients. Pediatrics, 116, 195–204.Google Scholar
Malone, RP, Gratz, SS, Delaney, MA, Hyman, SB (2005). Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs, 19, 923–934.Google Scholar
March, J, Silva, S, Petrycki, S, et al.; Treatment for Adolescents with Depression Study (TADS) Team (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA, 292, 807–820.Google ScholarPubMed
Marcus, RN, Owen, R, Kamen, L, et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry, 48, 1110–1119.Google ScholarPubMed
McClellan, L, Dominick, KC, Pedapati, EV, Wink, LK, Erickson, CA (2017). Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opin Investig Drugs, 26, 985–989.Google Scholar
McDougle, CJ, Scahill, L, Aman, MG, et al. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry, 162, 1142–1148.Google Scholar
Medicines for Children (2015). Unlicensed Medicines (online). Available at: www.medicinesforchildren.org.uk/unlicensed-medicines (last accessed 12.6.18).Google Scholar
Murray, ML, Thompson, M, Santosh, PJ, Wong, IC (2005). Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf, 28(12), 1151–1157.Google Scholar
National Collaborating Centre for Mental Health (2015). Depression in children and young people: identification and management in primary, community and secondary care. Clinical guideline [CG28]. London: National Institute for Health and Clinical Excellence.Google Scholar
Owen, R, Sikich, L, Marcus, RN, et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.Google Scholar
Politte, LC, Scahill, L, Figueroa, J, et al. (2018). A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology, 43, 1772–1778.Google Scholar
Rani, F, Murray, ML, Byrne, PJ, Wong, IC (2008). Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics, 121, 1002–1009.Google Scholar
Remington, G, Sloman, L, Konstantareas, M, Parker, K, Gow, R (2001). Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol, 21, 440–444.Google Scholar
Roessner, V, Plessen, KJ, Rothenberger, A, et al.; ESSTS Guidelines Group (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry, 20, 173–196.Google Scholar
Rosen, MS (2017). Lithium in child and adolescent bipolar disorder. Am J Psychiatry Resid J, 12, 3–5.Google Scholar
Royal College of Paediatrics and Child Health (2013). The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice. London: Royal College of Paediatrics and Child Health.Google Scholar
Royal College of Psychiatrists (2007). Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice, 2nd ed. College Report CR210. London: Royal College of Psychiatrists.Google Scholar
Ryan, ND (1990). Heterocyclic antidepressants in children and adolescents. J Child Adolesc Psychopharmacol, 1, 21–31.Google ScholarPubMed
Rylance, GW, Moreland, TA (1980). Drug level monitoring in paediatric practice. Arch Dis Child, 55, 89–98.CrossRefGoogle ScholarPubMed
Sandor, P (1995). Clinical management of Tourette’s syndrome and associated disorders. Can J Psychiatry, 40, 577–583.Google Scholar
Scahill, L, Erenberg, G, Berlin, CM Jr, et al.; Tourette Syndrome Association Medical Advisory Board: Practice Committee (2006). Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx, 3, 192–206.Google Scholar
Sharma, AN, Arango, C, Coghill, D, et al. (2016). BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol, 30, 416–421.Google Scholar
Shrestha, SS, Nelson, EE, Liow, JS, et al. (2014). Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry, 171, 323–331.CrossRefGoogle ScholarPubMed
Simonoff, E, Pickles, A, Charman, T, et al. (2008). Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry, 47, 921–929.Google Scholar
Sonuga-Barke, EJ, Swanson, JM, Coghill, D, Decory, HH, Hatch, SJ (2004). Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry, 4, 28.Google Scholar
Sparks, JA, Duncan, BL (2013). Outside the black box: re-assessing pediatric antidepressant prescription. J Can Acad Child Adolesc Psychiatry, 22, 240–246.Google Scholar
Stone, M, Laughren, T, Jones, ML, et al. (2009). Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, b2880.CrossRefGoogle ScholarPubMed
Usala, T, Clavenna, A, Zuddas, A, Bonati, M (2008). Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol, 18, 62–73.Google Scholar
Verdellen, C, van de Griendt, J, Hartmann, A, Murphy, T; ESSTS Guidelines Group (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry, 20, 197–207.Google Scholar
Zheng, W, Li, XB, Xiang, YQ, et al. (2016). Aripiprazole for Tourette’s syndrome: a systematic review and meta-analysis. Hum Psychopharmacol, 31, 11–18.Google Scholar